Mediwound reports first quarter 2025 financial results and provides corporate update

Value phase iii trial of escharex ® in venous leg ulcers advancing as planned nexobrid ® manufacturing expansion on track; full operational capacity expected by year-end 2025 first quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million conference call today, may 21 at 8:30am eastern time yavne, israel, may 21, 2025 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended march 31, 2025, and provided a corporate update.
MDWD Ratings Summary
MDWD Quant Ranking